vs
Side-by-side financial comparison of NICOLET BANKSHARES INC (NIC) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $104.0M, roughly 1.7× NICOLET BANKSHARES INC). NICOLET BANKSHARES INC runs the higher net margin — 38.8% vs 1.6%, a 37.1% gap on every dollar of revenue. On growth, NICOLET BANKSHARES INC posted the faster year-over-year revenue change (12.5% vs 5.0%). Over the past eight quarters, NICOLET BANKSHARES INC's revenue compounded faster (12.5% CAGR vs -0.2%).
Nicolet Bankshares, Inc. is a U.S. regional bank holding company based in Green Bay, Wisconsin. They are the parent company of Nicolet National Bank, the second largest Wisconsin-based bank.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
NIC vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $104.0M | $177.4M |
| Net Profit | $40.3M | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 48.3% | 3.9% |
| Net Margin | 38.8% | 1.6% |
| Revenue YoY | 12.5% | 5.0% |
| Net Profit YoY | 16.9% | — |
| EPS (diluted) | $2.63 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $104.0M | $196.9M | ||
| Q3 25 | $102.9M | $179.5M | ||
| Q2 25 | $95.7M | $181.1M | ||
| Q1 25 | $89.4M | $168.9M | ||
| Q4 24 | $92.4M | $187.3M | ||
| Q3 24 | $90.7M | $168.6M | ||
| Q2 24 | $85.0M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $40.3M | — | ||
| Q3 25 | $41.7M | $5.4M | ||
| Q2 25 | $36.0M | $-4.8M | ||
| Q1 25 | $32.6M | $4.8M | ||
| Q4 24 | $34.5M | — | ||
| Q3 24 | $32.5M | $-143.5M | ||
| Q2 24 | $29.3M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 48.3% | 1.2% | ||
| Q3 25 | 50.4% | 3.5% | ||
| Q2 25 | 46.8% | 4.7% | ||
| Q1 25 | 44.9% | 1.2% | ||
| Q4 24 | 46.8% | 13.2% | ||
| Q3 24 | 45.0% | -82.8% | ||
| Q2 24 | 43.3% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | 38.8% | — | ||
| Q3 25 | 40.6% | 3.0% | ||
| Q2 25 | 37.6% | -2.7% | ||
| Q1 25 | 36.4% | 2.8% | ||
| Q4 24 | 37.3% | — | ||
| Q3 24 | 35.8% | -85.1% | ||
| Q2 24 | 34.5% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $2.63 | $0.05 | ||
| Q3 25 | $2.73 | $0.12 | ||
| Q2 25 | $2.34 | $-0.11 | ||
| Q1 25 | $2.08 | $0.10 | ||
| Q4 24 | $2.21 | $0.38 | ||
| Q3 24 | $2.10 | $-3.11 | ||
| Q2 24 | $1.92 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $144.3M |
| Total DebtLower is stronger | $134.9M | — |
| Stockholders' EquityBook value | $1.3B | $653.9M |
| Total Assets | $9.2B | $1.2B |
| Debt / EquityLower = less leverage | 0.11× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | — | $238.4M | ||
| Q3 25 | — | $246.3M | ||
| Q2 25 | — | $445.9M | ||
| Q1 25 | — | $493.6M | ||
| Q4 24 | — | $484.6M | ||
| Q3 24 | — | $453.8M | ||
| Q2 24 | — | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | $134.9M | $372.2M | ||
| Q3 25 | $134.6M | $376.7M | ||
| Q2 25 | $134.3M | $580.5M | ||
| Q1 25 | $156.6M | $583.4M | ||
| Q4 24 | $161.4M | $585.3M | ||
| Q3 24 | $161.2M | — | ||
| Q2 24 | $162.4M | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.3B | $693.1M | ||
| Q3 25 | $1.2B | $727.2M | ||
| Q2 25 | $1.2B | $757.8M | ||
| Q1 25 | $1.2B | $798.5M | ||
| Q4 24 | $1.2B | $778.3M | ||
| Q3 24 | $1.1B | $749.6M | ||
| Q2 24 | $1.1B | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $9.2B | $1.3B | ||
| Q3 25 | $9.0B | $1.3B | ||
| Q2 25 | $8.9B | $1.5B | ||
| Q1 25 | $9.0B | $1.6B | ||
| Q4 24 | $8.8B | $1.6B | ||
| Q3 24 | $8.6B | $1.5B | ||
| Q2 24 | $8.6B | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | 0.11× | 0.54× | ||
| Q3 25 | 0.11× | 0.52× | ||
| Q2 25 | 0.11× | 0.77× | ||
| Q1 25 | 0.13× | 0.73× | ||
| Q4 24 | 0.14× | 0.75× | ||
| Q3 24 | 0.14× | — | ||
| Q2 24 | 0.15× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $153.5M | — |
| Free Cash FlowOCF − Capex | $149.4M | — |
| FCF MarginFCF / Revenue | 143.7% | — |
| Capex IntensityCapex / Revenue | 3.9% | — |
| Cash ConversionOCF / Net Profit | 3.81× | — |
| TTM Free Cash FlowTrailing 4 quarters | $275.0M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $153.5M | $43.7M | ||
| Q3 25 | $45.9M | $60.8M | ||
| Q2 25 | $38.9M | $12.0M | ||
| Q1 25 | $41.8M | $35.5M | ||
| Q4 24 | $133.7M | $33.1M | ||
| Q3 24 | $39.6M | $53.9M | ||
| Q2 24 | $37.3M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $149.4M | $43.5M | ||
| Q3 25 | $45.9M | $57.0M | ||
| Q2 25 | $38.4M | $9.3M | ||
| Q1 25 | $41.3M | $26.9M | ||
| Q4 24 | $116.8M | $31.0M | ||
| Q3 24 | $34.7M | $49.8M | ||
| Q2 24 | $34.4M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | 143.7% | 22.1% | ||
| Q3 25 | 44.6% | 31.7% | ||
| Q2 25 | 40.1% | 5.1% | ||
| Q1 25 | 46.2% | 15.9% | ||
| Q4 24 | 126.4% | 16.6% | ||
| Q3 24 | 38.3% | 29.6% | ||
| Q2 24 | 40.5% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 3.9% | 0.1% | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.6% | 1.5% | ||
| Q1 25 | 0.5% | 5.1% | ||
| Q4 24 | 18.3% | 1.1% | ||
| Q3 24 | 5.4% | 2.4% | ||
| Q2 24 | 3.5% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.81× | — | ||
| Q3 25 | 1.10× | 11.20× | ||
| Q2 25 | 1.08× | — | ||
| Q1 25 | 1.28× | 7.37× | ||
| Q4 24 | 3.88× | — | ||
| Q3 24 | 1.22× | — | ||
| Q2 24 | 1.28× | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NIC
Segment breakdown not available.
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
